Caplin Point Laboratories Limited · NSE:CAPLIPOINT
Caplin Point Laboratories — Q1 FY26 Earnings Presentation
20 slides from Caplin Point Laboratories's earnings presentation, August 2025
Slide 1: Earnings Presentation Q1 FY26
EARNINGS PRESENTATION Q1 FY26 Rated #1 in India for “Most Consistent Profitable Growth across the last 10 years” Second Largest wealth creator for the decade ending 2020* August 2025 www.caplinpoint.net #Value Research magazine – Wealth Insight June 2022 issue *The Economic Times
Slide 2: Evolution Over the Decades
Evolution Over the Decades Commences Capex expansion in multiple Incorporates Caplin Work on Regulated projects equaling Rs. 600 Steriles USA Inc for Listed on Stock Started outsourcing from Markets Injectable unit Started first commercial Cr. CRO wing Amaris launching own label in US Exchange China
Slide 3: Q1 FY26 Income Statement
Q1 FY26 Income Statement Revenue from Operations Gross Profit EBITDA 11.2% 15.2% 17.9% YoY YoY YoY 510 315 201 502 194 301 459 170 273 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 EBIT PAT Earnings Per Share 19.6% 20.7% YoY YoY 185 151 177 145 18.75 20.10 16.32 125 154 Q1
Slide 4: Q1 FY26 Profit Margins
Q1 FY26 Profit Margins Gross Profit Margins (%) EBITDA Margins (%) 61.7% 37.7% 36.7% 60.0% 59.6% 35.7% Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 EBIT Margins (%) PAT Margins (%) 34.6% 28.3% 33.5% 27.5% 32.3% 26.2% Q1 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q4 FY25 Q1 FY26 4
Slide 5: FY25 Income Statement
FY25 Income Statement Revenue from Operations Gross Profit EBITDA 14.4% 20.3% 20.2% YoY YoY YoY 1,937 743 1,167 618 970 1,694 FY24 FY25 FY24 FY25 FY24 FY25 EBIT PAT Profit Margins 19.9% 17.3% YoY YoY 57.3% 60.2% 677 541 35.1% 36.5% 32.1% 33.3% 565 461 26.2% 26.6% FY24 FY25 FY24 FY25 FY24 FY25 Gross
Slide 6: Leadership Team
Leadership Team Chairman Perspectives Management Team Commenting on the recent performance, Mr. C.C. Paarthipan, Chairman of Caplin Dr. Sridhar Ganesan Mr. Vivek Partheeban Point Laboratories said: • Managing Director • Chief Operating Officer We’re putting in place the right building blocks for bot
Slide 7: Q1 FY26 Highlights (Emerging Markets)
Q1 FY26 Highlights (Emerging Markets) 01 02 03 04 Company strengthens foothold in Latin Company initiates “China 2.0” strategy, Mexico Update – Company has filed Company has won tenders to the tune America with new Warehouse in Chile, aligning with new and existing partners 35+ products, with 17 app
Slide 8: Q1 FY26 Highlights (US and Regulated markets)
Q1 FY26 Highlights (US and Regulated markets) 01 02 03 04 CSL actively exploring additional Strong traction observed from recent Caplin Steriles reports strong Q1 Company has 38 ANDAs approved and 13 ANDA acquisitions, building on 3 specialty launches including performance across B2B and B2C under r
Slide 9: Research & Development Capabilities
Research & Development Capabilities 1 Caplin has 5 dedicated R&D setups (3 – DSIR approved). R&D Expense (Rs. Crore) R&D Expense as a % of Operating Revenue 2 Continuous capex investment of over Rs. 887 Cr over last 8 years towards 89 85 enhanced manufacturing and R&D capabilities, from internal acc
Slide 10: Revenue Break up and Manufacturing Strategy
Revenue Break up and Manufacturing Strategy Revenue by Business Segment Revenue by Channel FY25 Operating Revenue (Emerging Markets) (Emerging Markets) 35% 18% 6% 75% 25% 20% 76% 45% Africa US LATAM Generic Branded Generic Wholesale Retail Institutional Caplin covers a wide spectrum of pharmaceutica
Slide 11: Generics and Branded Generics Product Mix
Generics and Branded Generics Product Mix Non-Steroidal Antiinflammatory Antihelminthics/ Dewormer Analgesic Drugs-NSAIDS Antibiotic and Antifungal Antihypertensive drug Electrolytes 11
Slide 12: Caplin Point Structure
Caplin Point Structure Caplin Point Laboratories Caplin Point Far East Ltd Caplin Steriles Ltd (BSE: 524742| NSE: CAPLIPOINT) (India) Subsidiaries Manufacturing Units: Manufacturing Units: • CP I: Puducherry • Nuevos Eticos Neo Ethicals S.A. • CP IV: Gummidipoondi • CP X: Vishakhapatnam Guatemala •
Slide 13: Manufacturing and R&D Platform
Manufacturing and R&D Platform Location of Plants and Facilities Tamil Nadu, India 1. SIDCO, Kakkalur, Near Chennai 1 2 2. Gummidipoondi, Chennai (CP4) 43 3. Thervoy SIPCOT, Chennai 5 4. Corporate Office, Chennai 5. Suthukeny, Puducherry (CP1) 6. APIIC, Visakhapatnam CP I CP III Puducherry Chengalpa
Slide 14: Strategic Investments
Strategic Investments Project Summary Facility Location Product Target Market Status Timeline Lyophilized CP1, Suthukeny, Caplin Plant I Injectables and Dual Existing Markets Nearing Completion Q3 FY26 Puducherry Chamber Syringes. Caplin Steriles CP4, Line 5 – Completed. Injectable Vials and Gummidi
Slide 15: Caplin Point's Investment Case
Caplin Point’s Investment Case Core Business to show consistent Caplin’s core business which is focused on Latin America and Francophone Africa is expected to grow at a growth steady pace with industry-average margins and benchmark cashflows Aspiration is to have exceptional compliance record and fo
Slide 16: Experienced and Visionary Board of Directors
Experienced and Visionary Board of Directors Mr. C.C. Paarthipan Dr. Sridhar Ganesan Dr. C K Gariyali, IAS Dr. R Nagendran Mr S Deenadayalan Mr. R. Vijayaraghavan Chairman Managing Director Independent Director Independent Director Independent Director Independent Director 30+ Years of 35+ Years exp
Slide 17: Q1 FY26 Consolidated Income Statement
Q1 FY26 Consolidated Income Statement (Rs. in Cr) Q1 FY26 Q1 FY25 YoY (%) Q4 FY25 QoQ (%) FY25 FY24 YoY (%) Revenue from Operation 510.22 458.96 11.2% 502.45 1.5% 1,937.47 1,694.10 14.4% Other Income 23.14 18.56 24.7% 25.74 (10.1)% 96.43 66.94 Total Revenue 533.36 477.52 11.7% 528.19 1.0% 2,033.90 1
Slide 18: Visit Our Real Time ESG Disclosure Platform
Visit Our Real Time ESG Disclosure Platform At the core of our ethos lies a steadfast commitment to embedding environmental, social, and governance principles into our operations. Map our ESG framework with 35+ different frameworks Download ESG data Access to ESG factsheet Click to access ESG Profil
Slide 19: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 20: Contact
Mr G Venkatram investors@caplinpoint.net Simran Malhotra / Akshay Hirani caplinpoint@churchgatepartners.com 524742 CAPLIPOINT CIN: L24231TN1990PLC019053 ISIN: INE475E01026 |DUNS:86-148-4556 | WWW.CAPLINPOINT.NET ©2018, Caplin Point Laboratories Limited – All Rights Reserved. “Caplin Point” and The C
Caplin Point Laboratories — Q1 FY26 Earnings Presentation on 6ix